EAU 2026 | Treatment de-intensification in NMIBC: selecting the right patients

Roberto Contieri • 15 Mar 2026

EAU 2026

Roberto Contieri, MD, Humanitas University, Rozzano, Italy, discusses the potential benefits of an de-escalated treatment strategy as an alternative to the classic approach for patients with low-grade non-muscle-invasive bladder cancer (NMIBC), including office fulguration, laser ablation, active surveillance, and chemoablation. Dr Contieri highlights the importance of selecting the right patients for this approach, such as those with a history of low-grade tumors and small recurrences, and notes that novel delivery systems and agents, such as mitomycin and UGN-102, are showing promising results in achieving complete response rates. This interview took place at the 41st Annual EAU Congress in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.